Antiulcerant Drugs: Global Markets to 2022 – ResearchAndMarkets.com

The “Antiulcerant
Drugs: Global Markets to 2022” report has been added to ResearchAndMarkets.com’s
offering.

The global antiulcerant drugs market growth outlook is positive with
significant growth potential for antiulcerant drugs market in emerging
countries. Rising disposable income in developed countries, growing
awareness of the disease, busy lifestyles, technological advances such
as big data, 3D printing and IoT is aiding the antiulcerant drugs market
growth.

The market for antiulcerant drugs is fragmented with a large number of
players. Major players in the market are AstraZeneca PLC, Allergan plc,
Daewoong Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda
Pharmaceutical Company others. Proton Pump Inhibitors accounted for the
largest share of the market for antiulcerant drugs market in 2017. The
highest growth is projected to come from H2 Receptor Antagonists
segment. Major factors included an aging population, sedentary
lifestyles and increasing awareness on ulcer disease.

North America is the largest market for antiulcerant drugs market. It
was followed by Asia Pacific and Western Europe. Going forward, Africa
is expected to witness the fastest growth in the antiulcerant drugs
market, followed by North America.

The USA is the largest market in terms of value and in the antiulcerant
drugs market. India and China are forecasted to have the fastest growth.
The market is challenged by restraints such as unfavorable laws for drug
patents and rising trade protectionism.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/dx47qb/antiulcerant?w=4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005647/en/

Leave a Comment